AbCellera Biologics (ABCL) Non Operating Income (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Non Operating Income came in at $8.0 million in Q1 2026, down 17.51% YoY from $9.7 million in Q1 2025, and down 12.12% on a QoQ basis from $9.1 million in Q4 2025.
AbCellera Biologics (ABCL) Non Operating Income (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Non Operating Income data on file, last reported at $8.0 million in Q1 2026.
- Quarterly Non Operating Income fell 17.51% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.8 million (down 66.21% YoY) and the FY2025 annual result came in at $39.5 million, down 65.46% from the prior year.
- Non Operating Income declined to $8.0 million in Q1 2026, from $9.1 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $45.3 million in Q2 2024 to a low of $1.5 million in Q2 2022.
- A 5-year average of $14.6 million and a median of $12.1 million in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income surged 786.42% — and 2025, when it sank 75.8%.
- Tracing ABCL's Non Operating Income over 5 years: stood at $6.4 million in 2022, then surged by 174.13% to $17.5 million in 2023, then surged by 48.56% to $25.9 million in 2024, then sank by 64.97% to $9.1 million in 2025, then declined by 12.12% to $8.0 million in 2026.
- The last three Non Operating Income figures came in at $8.0 million (Q1 2026), $9.1 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 3.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.81 Mn |
| Mar 31, 2026 | 7.98 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Sep 30, 2025 | 7.51 Mn |
| Jun 30, 2025 | 13.24 Mn |
| Mar 31, 2025 | 9.68 Mn |
| Dec 31, 2024 | 25.93 Mn |
| Sep 30, 2024 | 31.03 Mn |
| Jun 30, 2024 | 45.27 Mn |
| Mar 31, 2024 | 12.15 Mn |
| Dec 31, 2023 | 17.45 Mn |
| Sep 30, 2023 | 15.61 Mn |
| Jun 30, 2023 | 13.39 Mn |
| Mar 31, 2023 | 16.73 Mn |
| Dec 31, 2022 | 6.37 Mn |
| Sep 30, 2022 | 8.85 Mn |
| Jun 30, 2022 | 1.51 Mn |
| Mar 31, 2022 | 5.86 Mn |
| Dec 31, 2021 | 3.16 Mn |
| Sep 30, 2021 | 3.12 Mn |